loading page

To what extent can we achieve mineral bone metabolism treatment targets suggested by KDIGO guidelines among chronic kidney disease stage 3-5 non-dialysis patients?
  • +5
  • Mevlut Tamer Dincer,
  • Seyda Gul Ozcan,
  • Selma Alagoz,
  • Cebrail Karaca,
  • Sibel Hamarat Gulcicek,
  • Sinan Trabulus,
  • Meltem Pekpak,
  • Nurhan Seyahi
Mevlut Tamer Dincer
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile
Seyda Gul Ozcan
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile
Selma Alagoz
Istanbul Bagcilar Training and Research Hospital
Author Profile
Cebrail Karaca
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile
Sibel Hamarat Gulcicek
Istanbul Teaching and Research Hospital
Author Profile
Sinan Trabulus
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile
Meltem Pekpak
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile
Nurhan Seyahi
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile

Abstract

Background Real-life data on the predialysis management of chronic kidney disease (CKD) is scarce. We aimed to investigate the current clinical practice and compliance among nephrologists with KDIGO CKD mineral bone disorders (MBD) guidelines. Methods We performed a multicenter cross-sectional study. We recruited stage 3-5 non-dialysis (ND) CKD patients and recorded data related to CKD MBD from two consecutive outpatient clinical visits apart 3 to 6 months. We calculated therapeutic inertia for hyperphosphatemia, hypocalcemia, hyperparathyroidism, and hypovitaminosis D and overtreatment for hypophosphatemia, hypercalcemia, hypoparathyroidism, and hypervitaminosis D. Results We examined a total of 302 patients (male: 48.7%, median age: 67 years). The persistence of low 25-OH vitamin D levels (61.7%) was the most common laboratory abnormality related to CKD-MBD, followed by hyperparathyroidism (14.8%), hyperphosphatemia (7.9%), and hypocalcemia (0.0%). According to our results, therapeutic inertia seems to be a more common problem than overtreatment for all the CKD-MBD laboratory parameters that we examined. Therapeutic inertia frequency was highest for hypovitaminosis D (81.1%), followed by hypocalcemia (75.0%), hyperparathyroidism (59.0%), and hyperphosphatemia (30.4%), respectively. Conclusion We found that CKD-MBD is not optimally managed in CKD stage 3-5 ND patients. Clinicians should have an active attitude regarding the correction of MBD even at the earlier stages of CKD.

Peer review status:UNDER REVIEW

19 Jan 2021Submitted to International Journal of Clinical Practice
21 Jan 2021Assigned to Editor
21 Jan 2021Submission Checks Completed
25 May 2021Reviewer(s) Assigned